Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | JUN | P05412 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27706029 | 1.00 | MKNK1 (0.50) | MKNK1MKNK2NFE2L2CYP1A1CYP1A2 | |
| SCHEMBL4258009 | 0.89 | KMT2A (0.56) | MKNK1MKNK2NFE2L2CYP1A1CYP1A2 | |
| SCHEMBL4255157 | 0.88 | MKNK1 (0.49) | MKNK1MKNK2NFE2L2CYP1A1CYP1A2 | |
| SCHEMBL27706028 | 0.88 | MKNK1 (0.49) | MKNK1MKNK2NFE2L2CYP1A1CYP1A2 | |
| SCHEMBL4262713 | 0.87 | NFE2L2 (0.50) | MKNK1MKNK2NFE2L2CYP1A1CYP1A2 | |
| SCHEMBL27726712 | 0.87 | NFE2L2 (0.50) | MKNK1MKNK2NFE2L2CYP1A1CYP1A2 | |
| SCHEMBL27738949 | 0.86 | CA12 (0.43) | MKNK1MKNK2CYP1A2CYP3A4CYP1B1 | |
| SCHEMBL5417556 | 0.86 | CA12 (0.43) | MKNK1MKNK2CYP1A2CYP3A4CYP1B1 | |
| SCHEMBL27717768 | 0.84 | CYP1A2 (0.46) | NFE2L2CYP1A1CYP1A2CYP3A4CYP1B1 | |
| SCHEMBL5414597 | 0.84 | CYP1A2 (0.46) | NFE2L2CYP1A1CYP1A2CYP3A4CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904471-B1 | HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2009-10-21 | — | — | EP | claimed |
| CN-101208325-A | Heteroarylvinyl derivatives, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-06-25 | — | — | CN | claimed |
| US-7208506-B2 | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | claimed |
| US-20070010564-A1 | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | claimed |
| EP-1904471-B1 | HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2009-10-21 | — | — | EP | disclosed |
| CN-101208325-A | Heteroarylvinyl derivatives, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-06-25 | — | — | CN | disclosed |
| US-7208506-B2 | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070010564-A1 | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010564-A1 | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents | CYP3A43, CYP1A1, CYP3A5 | MKNK1 4602/4885MKNK2 4717/4885NFE2L2 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.